Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02946125 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil
A Phase 2 study, sponsored by Eyenovia.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02946125 is a Phase 2 study that has completed, run by Eyenovia. The registered enrollment target is 12 participants.
The verdict
NCT02946125, a Phase 2 study, has completed, sponsored by Eyenovia.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a Phase 2 study to investigate the safety, efficacy and pharmacokinetics of EYN-1601 for dilation of the pupil. A single microdose of EYN-1601 will be compared to single doses of commercially available phenylephrine hydrochloride 2.5% and 10% ophthalmic solutions.
Interventions
- COMBINATION_PRODUCT MDD-administered EYN-1601
- DRUG Phenylephrine 2.5% Eyedrop
- DRUG Phenylephrine 10% Eyedrop
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-10 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02946125
The ClinicalTrials.gov registry entry for NCT02946125 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eyenovia, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which MDD-administered EYN-1601 is the first listed.
NCT02946125 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02946125 about?
NCT02946125 is a clinical study titled "Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil". This is a Phase 2 study to investigate the safety, efficacy and pharmacokinetics of EYN-1601 for dilation of the pupil. A single microdose of EYN-1601 will be compared to single doses of commercially available phenylephrine hydrochloride 2.5% and 10% ophthalmic solutions.
What is the current status of trial NCT02946125?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-10. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02946125?
The interventions under investigation include: MDD-administered EYN-1601 (COMBINATION_PRODUCT), Phenylephrine 2.5% Eyedrop (DRUG), Phenylephrine 10% Eyedrop (DRUG).
Who is sponsoring clinical trial NCT02946125?
This trial is sponsored by Eyenovia, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.